Masimo price target raised to $210 from $180 at Piper Sandler

Piper Sandler analyst Jason Bednar raised the firm’s price target on Masimo (MASI) to $210 from $180 and keeps an Overweight rating on the shares. Noting the stock is its top idea for next year, the firm highlights that Masimo participates in one of the better duopolies across MedTech and that it believes the company should see a large reset higher during 2025 in both operating margin and EPS following the impending consumer divestiture, which should support a premium valuation for multiple years until that margin upside is realized.